



The patients with HBV-related decompensated liver cirrhosis received UC-MSc transfusions on weeks 0, 4 and 8 (A). The overall survival rate was significantly higher in the UC-MSc treatment group than in the control group during the 13- to 75-month follow-up (B). There was not any significant difference in the HCC diseases free survival rate between the UC-MSc treatment group and control group within 8 months or between 8 months and 75 months (C).